Core Viewpoint - GE Vernova (GEV) has been trending as a stock of interest, with a notable performance compared to the broader market and its industry [1][2]. Earnings Estimates - For the current quarter, GE Vernova is projected to report earnings of $1.58 per share, reflecting a year-over-year increase of +122.5%. The consensus estimate has seen a slight decrease of -2.7% over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year stands at $7.21, indicating a +29.2% change from the previous year, with a minor increase of +0.8% in the last month [5]. - For the next fiscal year, the earnings estimate is $11.34, suggesting a +57.2% increase compared to the prior year, with a recent adjustment of +0.5% [6]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $8.82 billion, which represents a year-over-year growth of +7.5%. For the current and next fiscal years, the sales estimates are $37.21 billion and $40.94 billion, indicating growth rates of +6.5% and +10%, respectively [11]. Last Reported Results - In the last reported quarter, GE Vernova achieved revenues of $8.03 billion, marking a +10.6% increase year-over-year. The EPS was $0.91, a significant improvement from -$0.41 a year ago. The revenue exceeded the Zacks Consensus Estimate of $7.54 billion by +6.46%, and the EPS surpassed estimates by +102.22% [12]. Valuation - GE Vernova is graded C on the Zacks Value Style Score, suggesting that it is trading at par with its peers. This assessment is based on various valuation metrics, including price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) [17].

Core Viewpoint - Johnson & Johnson is currently under observation due to its stock performance and potential future direction, particularly in relation to earnings estimates and revenue growth [1][2]. Earnings Estimate Revisions - For the current quarter, Johnson & Johnson is expected to report earnings of $2.64 per share, reflecting a decrease of -6.4% year-over-year, with a slight increase of +0.5% in the Zacks Consensus Estimate over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $10.62, indicating a growth of +6.4% from the previous year, with a minor adjustment of +0.1% in the last month [5]. - For the next fiscal year, the earnings estimate stands at $11, suggesting a growth of +3.6% compared to the prior year, with a recent increase of +0.2% [6]. - Johnson & Johnson holds a Zacks Rank 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $22.77 billion, representing a year-over-year increase of +1.4% [11]. - For the current fiscal year, the revenue estimates are $91.19 billion and $94.24 billion, indicating growth rates of +2.7% and +3.4%, respectively [11]. Last Reported Results and Surprise History - In the last reported quarter, Johnson & Johnson achieved revenues of $21.89 billion, a year-over-year increase of +2.4%, and an EPS of $2.77, up from $2.71 a year ago [12]. - The company exceeded the Zacks Consensus Estimate for revenues by +1.26% and for EPS by +7.78% [12]. - Johnson & Johnson has consistently beaten consensus EPS and revenue estimates over the past four quarters [13]. Valuation - Johnson & Johnson is graded B in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [17].

Core Viewpoint - MicroStrategy's stock performance has been under scrutiny, with recent trends indicating a potential for growth or decline based on earnings estimates and revenue projections [1][2]. Earnings Estimate Revisions - For the current quarter, MicroStrategy is expected to report a loss of $0.12 per share, reflecting an increase of +84.2% compared to the same quarter last year [5]. - The consensus earnings estimate for the current fiscal year is -$15.73, indicating a significant year-over-year decline of -134.1% [5]. - For the next fiscal year, the consensus earnings estimate is $0.4, which represents a growth of +97.5% from the previous year [6]. - MicroStrategy holds a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $112.15 million, showing a year-over-year increase of +0.6% [11]. - For the current fiscal year, the sales estimate is $466.5 million, indicating a growth of +0.7%, while the next fiscal year is projected at $484.8 million, reflecting a +3.9% change [11]. Last Reported Results and Surprise History - In the last reported quarter, MicroStrategy generated revenues of $111.07 million, which is a decrease of -3.6% year-over-year [12]. - The reported EPS was -$16.49, compared to -$0.83 a year ago, with a revenue surprise of -4.01% against the Zacks Consensus Estimate [12]. - Over the last four quarters, MicroStrategy has surpassed consensus EPS estimates multiple times and has also exceeded revenue estimates during this period [13]. Valuation - MicroStrategy is currently graded F on the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17]. - Valuation metrics such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued or undervalued [15][16].

Core Viewpoint - Wix.com has recently gained attention as one of the most searched stocks, prompting analysis of factors influencing its future stock performance [1] Earnings Estimate Revisions - Wix.com is expected to report earnings of $1.79 per share for the current quarter, reflecting a year-over-year increase of +7.2%, although the Zacks Consensus Estimate has decreased by -5.2% over the last 30 days [5] - For the current fiscal year, the consensus earnings estimate is $7.27, indicating a +13.8% change from the previous year, with a recent downward revision of -6.4% [5] - The next fiscal year's consensus earnings estimate stands at $8.68, suggesting a +19.4% increase compared to the prior year, with a slight decrease of -1.8% in the last month [6] - Wix.com holds a Zacks Rank 3 (Hold), indicating a neutral outlook based on recent changes in earnings estimates and other related factors [7] Revenue Growth Forecast - The consensus sales estimate for Wix.com is $487.58 million for the current quarter, representing a year-over-year growth of +11.9% [11] - For the current fiscal year, revenue estimates are $1.98 billion, indicating a +12.7% change, while the next fiscal year's estimate is $2.22 billion, reflecting a +12.1% increase [11] Last Reported Results and Surprise History - In the last reported quarter, Wix.com achieved revenues of $473.65 million, a +12.8% increase year-over-year, with an EPS of $1.55 compared to $1.29 a year ago [12] - The reported revenues exceeded the Zacks Consensus Estimate of $471.78 million by +0.4%, although the EPS fell short by -6.63% [12] - Over the past four quarters, Wix.com has surpassed consensus EPS estimates three times and revenue estimates three times [13] Valuation - Wix.com is currently graded D in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [15][16]

Core Viewpoint - GE Vernova has shown significant stock performance, returning +30.8% over the past month, outperforming the S&P 500 composite's +6.7% and the Zacks Alternative Energy - Other industry's +17% [2] Earnings Estimates - GE Vernova is expected to post earnings of $1.57 per share for the current quarter, reflecting a year-over-year increase of +121.1% [5] - The consensus earnings estimate for the current fiscal year is $7.16, indicating a year-over-year change of +28.3% [5] - For the next fiscal year, the consensus earnings estimate is $11.26, representing a +57.3% change from the previous year [6] - Over the last 30 days, the earnings estimates have changed by +8.9% for the current quarter and -0.3% for the current fiscal year [5][6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $8.76 billion, indicating a year-over-year change of +6.8% [11] - For the current fiscal year, the sales estimate is $36.98 billion, reflecting a +5.9% change, while the next fiscal year's estimate is $40.44 billion, indicating a +9.4% change [11] Last Reported Results - GE Vernova reported revenues of $8.03 billion in the last quarter, a year-over-year increase of +10.6% [12] - The EPS for the same period was $0.91, compared to -$0.41 a year ago, with a revenue surprise of +6.46% and an EPS surprise of +102.22% [12] Valuation - GE Vernova has a Zacks Value Style Score of D, indicating it is trading at a premium to its peers [17] - The assessment of valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) is crucial for determining the stock's valuation relative to its historical values and peers [15][16]

Core Viewpoint - GE Vernova has shown significant stock performance, returning +31.9% over the past month, outperforming the S&P 500 composite's +9% and the Zacks Alternative Energy - Other industry's +22.2% [2] Earnings Estimate Revisions - GE Vernova is expected to post earnings of $1.44 per share for the current quarter, reflecting a year-over-year increase of +102.8% with a 30-day change of +5.2% in the Zacks Consensus Estimate [5] - For the current fiscal year, the consensus earnings estimate is $7.18, indicating a +28.7% change from the previous year, with a 30-day change of +11.4% [5] - The next fiscal year's consensus earnings estimate is $11.10, showing a +54.7% change from the prior year, with a slight 30-day change of +0.1% [6] - The Zacks Rank for GE Vernova is 3 (Hold), indicating a neutral outlook based on earnings estimate revisions [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $8.75 billion, representing a year-over-year change of +6.7% [11] - For the current fiscal year, the sales estimate is $36.98 billion, indicating a +5.9% change, while the next fiscal year's estimate is $40.4 billion, reflecting a +9.3% change [11] Last Reported Results and Surprise History - In the last reported quarter, GE Vernova achieved revenues of $8.03 billion, a +10.6% year-over-year increase, and an EPS of $0.91 compared to -$0.41 a year ago [12] - The reported revenues exceeded the Zacks Consensus Estimate of $7.54 billion by +6.46%, and the EPS surprise was +102.22% [12] - Over the last four quarters, GE Vernova surpassed consensus EPS estimates three times and revenue estimates two times [13] Valuation - GE Vernova has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [17]

Gray Media (GTN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this broadcast television company have returned +38.1%, compared to the Zacks S&P 500 composite's +9.1% change. During this period, the Zacks Broadcast Radio and Television industry, which Gray Media falls in, has gained 18.5%. The key question now is: What could be the stock's future direc ...

Core Viewpoint - Boston Scientific (BSX) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimate Revisions - For the current quarter, Boston Scientific is expected to report earnings of $0.72 per share, reflecting a year-over-year increase of +16.1% [5] - The Zacks Consensus Estimate for the current fiscal year is $2.91, indicating a year-over-year change of +15.9%, with a +2.2% revision over the last 30 days [5] - The consensus earnings estimate for the next fiscal year is $3.26, showing a change of +11.8% from the previous year, with a +0.9% revision over the past month [6] - Boston Scientific holds a Zacks Rank 2 (Buy), suggesting a favorable outlook based on recent earnings estimate changes [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.89 billion, indicating a year-over-year increase of +18.6% [11] - For the current fiscal year, the sales estimate is $19.49 billion, reflecting a change of +16.4%, while the next fiscal year's estimate is $21.55 billion, indicating a +10.6% change [11] Last Reported Results and Surprise History - In the last reported quarter, Boston Scientific achieved revenues of $4.66 billion, a year-over-year increase of +20.9%, and an EPS of $0.75 compared to $0.56 a year ago [12] - The company exceeded the Zacks Consensus Estimate for revenues by +2.31% and for EPS by +11.94% [12] - Boston Scientific has consistently beaten consensus EPS and revenue estimates over the past four quarters [13] Valuation - Boston Scientific is graded D on the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17] - Valuation metrics such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [15][16] Bottom Line - The information presented suggests that Boston Scientific may outperform the broader market in the near term, supported by its Zacks Rank 2 [18]

Core Viewpoint - Arch Capital Group (ACGL) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimates - Arch Capital is expected to report earnings of $2.34 per share for the current quarter, reflecting a year-over-year decline of 9% [5] - The consensus earnings estimate for the current fiscal year is $7.89, indicating a year-over-year decrease of 15% [5] - For the next fiscal year, the consensus earnings estimate is $9.57, showing a year-over-year increase of 21.2% [6] - Over the last 30 days, the earnings estimates have seen slight changes of -1.8% for the current quarter and -0.1% for the current fiscal year [5][6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.68 billion, representing a year-over-year increase of 18.8% [11] - For the current fiscal year, the revenue estimate is $18.91 billion, indicating a growth of 13.8%, while the next fiscal year is projected at $20.32 billion, reflecting a growth of 7.5% [11] Last Reported Results and Surprise History - In the last reported quarter, Arch Capital achieved revenues of $4.56 billion, a year-over-year increase of 21.3% [12] - The EPS for the same period was $1.54, down from $2.45 a year ago, with a surprise of +12.41% compared to the consensus estimate [12][13] - The company has consistently beaten consensus EPS estimates in the last four quarters and topped revenue estimates three times [13] Valuation - Arch Capital has a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [7][18] - The Zacks Value Style Score for Arch Capital is graded B, indicating it is trading at a discount compared to its peers [17]

Core Viewpoint - Novo Nordisk's stock has experienced a decline of -2.2% over the past month, underperforming the Zacks S&P 500 composite's -0.5% change and the Zacks Large Cap Pharmaceuticals industry's -2% loss, raising questions about its near-term performance [1] Earnings Estimate Revisions - The consensus earnings estimate for the current quarter is $0.91 per share, reflecting a year-over-year increase of +9.6%, with a recent change of +2.2% over the last 30 days [4] - For the current fiscal year, the consensus earnings estimate is $3.85, indicating a +17.4% change from the previous year, with a +1.3% change in the last 30 days [4] - The next fiscal year's consensus earnings estimate is $4.71, showing a +22.4% change from the prior year, with a +2.1% change over the past month [5] - Novo Nordisk holds a Zacks Rank 3 (Hold), influenced by recent changes in consensus estimates and other earnings-related factors [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $11.33 billion, indicating a year-over-year increase of +19.1% [10] - The sales estimates for the current and next fiscal years are $50.66 billion and $58.15 billion, reflecting changes of +20.3% and +14.8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Novo Nordisk achieved revenues of $12.26 billion, a year-over-year increase of +28.9%, and an EPS of $0.91 compared to $0.71 a year ago [11] - The reported revenues exceeded the Zacks Consensus Estimate of $11.34 billion by +8.11%, and the EPS surprise was +9.64% [11] - Over the last four quarters, Novo Nordisk surpassed consensus EPS estimates twice and revenue estimates twice [12] Valuation - Novo Nordisk is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers [16]